<p><strong>紐約，NY / ACCESS Newswire /2025 年 8 月 10 日/</strong> 如果您在 <strong>Biohaven Ltd.</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
<p>https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28</p>
<p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
<p><strong>訴訟：</strong> 針對 Biohaven Ltd.提起了一項集體訴訟，旨在追回在 2023 年 3 月 24 日至 2025 年 5 月 14 日期間因涉嫌證券欺詐而受到不利影響的股東的損失。</p>
<p><strong>案件詳情：</strong> 提交的投訴指控被告作出了虛假陳述和/或隱瞞了以下事實：(i) 該公司的產品候選藥物 troriluzole 作為 SCA 治療的監管前景和/或 Biohaven 為支持 troriluzole 在該適應症下的監管批准所提交的數據的充分性被誇大；(ii) BHV-7000 作為雙相情感障礙治療的療效和臨牀前景同樣被誇大；(iii) 一旦上述所有情況被揭露，可能會對 Biohaven 的業務和財務狀況產生重大負面影響；(iv) 因此，被告的公開聲明在所有相關時間都是實質性虛假和誤導的。</p>
<p><strong>接下來會發生什麼？</strong> 如果您在相關時間段內在 Biohaven Ltd.股票中遭受損失——即使您仍持有股票——請訪問 https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28 以瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
<p><strong>為什麼選擇 LEVI &amp; KORSINSKY：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為一家全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中贏得了良好的記錄。該公司在複雜證券訴訟中代表投資者方面擁有豐富的專業知識，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 名報告中被評為美國頂級證券訴訟公司之一。律師廣告。以往的結果並不保證類似的結果。</p>
<p><strong>聯繫方式：</strong></p>
<p>Levi &amp; Korsinsky, LLP</p>
<p>Joseph E. Levi, Esq.</p>
<p>Ed Korsinsky, Esq.</p>
<p>33 Whitehall Street, 17th Floor</p>
<p>紐約，NY 10004</p>
<p>jlevi@levikorsinsky.com</p>
<p>電話：(212) 363-7500</p>
<p>傳真：(212) 363-7171</p>
<p>https://zlk.com/</p>
<p><strong>來源：</strong> Levi &amp; Korsinsky, LLP</p>
<p>查看 ACCESS Newswire 上的原始新聞稿</p>

Biohaven藥業

<p>Levi & Korsinsky LLP 正在敦促在 Biohaven Ltd. (BHVN) 上虧損的投資者在 2025 年 9 月 12 日之前採取行動，參與與涉嫌證券欺詐相關的集體訴訟。訴訟聲稱該公司對其產品候選者做出了虛假陳述，這對其業務和財務狀況產生了負面影響。鼓勵在 2023 年 3 月 24 日至 2025 年 5 月 14 日之間遭受損失的投資者尋求無任何費用或義務的賠償。Levi & Korsinsky 在證券訴訟方面有着良好的業績記錄</p>

<p><strong>NEW YORK, NY / ACCESS Newswire / August 10, 2025 /</strong> If you suffered a loss on your <strong>Biohaven Ltd.</strong> investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:</p>
<div class="lb-trans"><p><strong>紐約，NY / ACCESS Newswire /2025 年 8 月 10 日/</strong> 如果您在 <strong>Biohaven Ltd.</strong> 的投資中遭受損失，並希望瞭解根據聯邦證券法的潛在賠償，請點擊以下鏈接獲取更多信息：</p>
</div><p>https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28</p>
<div class="lb-trans"><p>https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28</p>
</div><p>or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.</p>
<div class="lb-trans"><p>或通過電子郵件聯繫 Joseph E. Levi 律師，郵箱為 jlevi@levikorsinsky.com，或撥打 (212) 363-7500 與我們經驗豐富的股東倡導團隊聯繫。</p>
</div><p><strong>THE LAWSUIT:</strong> A class action securities lawsuit was filed against Biohaven Ltd. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025.</p>
<div class="lb-trans"><p><strong>訴訟：</strong> 針對 Biohaven Ltd.提起了一項集體訴訟，旨在追回在 2023 年 3 月 24 日至 2025 年 5 月 14 日期間因涉嫌證券欺詐而受到不利影響的股東的損失。</p>
</div><p><strong>CASE DETAILS:</strong> The filed complaint alleges that defendants made false statements and/or concealed that: (i) The company's product candidate, troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.</p>
<div class="lb-trans"><p><strong>案件詳情：</strong> 提交的投訴指控被告作出了虛假陳述和/或隱瞞了以下事實：(i) 該公司的產品候選藥物 troriluzole 作為 SCA 治療的監管前景和/或 Biohaven 為支持 troriluzole 在該適應症下的監管批准所提交的數據的充分性被誇大；(ii) BHV-7000 作為雙相情感障礙治療的療效和臨牀前景同樣被誇大；(iii) 一旦上述所有情況被揭露，可能會對 Biohaven 的業務和財務狀況產生重大負面影響；(iv) 因此，被告的公開聲明在所有相關時間都是實質性虛假和誤導的。</p>
</div><p><strong>WHAT'S NEXT?</strong> If you suffered a loss in Biohaven Ltd. stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28 to learn about your rights to seek a recovery. <strong>There is no cost or obligation to participate.</strong></p>
<div class="lb-trans"><p><strong>接下來會發生什麼？</strong> 如果您在相關時間段內在 Biohaven Ltd.股票中遭受損失——即使您仍持有股票——請訪問 https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=160641&amp;wire=1&amp;utm_campaign=28 以瞭解您尋求賠償的權利。<strong>參與沒有費用或義務。</strong></p>
</div><p><strong>WHY LEVI &amp; KORSINSKY:</strong> Over the past 20 years, Levi &amp; Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi &amp; Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>為什麼選擇 LEVI &amp; KORSINSKY：</strong> 在過去 20 年中，Levi &amp; Korsinsky LLP 已建立為一家全國知名的證券訴訟公司，為受害股東爭取了數億美元，並在高風險案件中贏得了良好的記錄。該公司在複雜證券訴訟中代表投資者方面擁有豐富的專業知識，並擁有超過 70 名員工為客户服務。連續七年，Levi &amp; Korsinsky 在 ISS 證券集體訴訟服務的前 50 名報告中被評為美國頂級證券訴訟公司之一。律師廣告。以往的結果並不保證類似的結果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p>Levi &amp; Korsinsky, LLP</p>
</div><p>Joseph E. Levi, Esq.</p>
<div class="lb-trans"><p>Joseph E. Levi, Esq.</p>
</div><p>Ed Korsinsky, Esq.</p>
<div class="lb-trans"><p>Ed Korsinsky, Esq.</p>
</div><p>33 Whitehall Street, 17th Floor</p>
<div class="lb-trans"><p>33 Whitehall Street, 17th Floor</p>
</div><p>New York, NY 10004</p>
<div class="lb-trans"><p>紐約，NY 10004</p>
</div><p>jlevi@levikorsinsky.com</p>
<div class="lb-trans"><p>jlevi@levikorsinsky.com</p>
</div><p>Tel: (212) 363-7500</p>
<div class="lb-trans"><p>電話：(212) 363-7500</p>
</div><p>Fax: (212) 363-7171</p>
<div class="lb-trans"><p>傳真：(212) 363-7171</p>
</div><p>https://zlk.com/</p>
<div class="lb-trans"><p>https://zlk.com/</p>
</div><p><strong>SOURCE:</strong> Levi &amp; Korsinsky, LLP</p>
<div class="lb-trans"><p><strong>來源：</strong> Levi &amp; Korsinsky, LLP</p>
</div><p>View the original press release on ACCESS Newswire</p>
<div class="lb-trans"><p>查看 ACCESS Newswire 上的原始新聞稿</p>
</div>

您是否在 Biohaven Ltd. (BHVN) 上遭受了損失？Levi & Korsinsky 敦促投資者在2025年9月12日之前採取行動